Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2007

View Archived Issues

Takeda reports first half ended September 30, 2007 results

DOR BioPharma enters cooperative agreement for RiVax with Walter Reed Army Institute

PhotoCure to de-merge its cancer-focused drug delivery subsidiary PCI Biotech

Phase III clinical study of ALK-Abello's grass pollen vaccine fails to meet primary endpoint

Peregrine receives approval in Georgia to initiate phase II trial of bavituximab

European Commission endorses positive opinion of EMEA for sanofi-aventis' Acomplia

EMEA grants orphan drug status to Vx-001 for non-small cell lung cancer

Celgene acquires Pharmion

Quark initiates phase I clinical trial of AKIi-5 for acute renal failure

BioXell initiates phase IIa trial of elocalcitol for male infertility

Takeda establishes Takeda San Francisco for therapeutic antibody research

KCNQ2/3 channel opener from ICAgen shows activity in pain in vivo models

NIAID sponsors phase I trial of Avant's E. coli-cholera vaccine Peru-15 pCTB

Small peptide inhibitor of PKC gamma shows activity in neuropathic pain models

Inflazyme sells majority of its research and development assets to Biolipox

Novel therapeutic agents for respiratory and allergic disorders described in recent patents

Recent Novartis patent discloses novel agents for renal failure

Studies describe novel non-nucleoside HCV RNA polymerase inhibitor GS-9190

Benefits of ranolazine treatment seen in MERLIN-TIMI 36 trial

AZD-9056 studied in healthy volunteers and rheumatoid arthritis patients

AMG-108 not significantly effective in knee osteoarthritis patients

Targeted Genetics releases findings from study of tgAAC94 in inflammatory arthritis

Actelion patents novel dual orexin OX1/OX2 receptor antagonists for eating disorders

Marketing and sale of Novartis' Prexige suspended in U.K. and Germany

FDA approves supplemental NDA for Avalide for hypertension

Chugai and Roche file FDA BLA for Actemra in RA indication

CHMP recommends Merck, Sharp and Dohme's Ivemend for nausea with chemotherapy

Abilify receives FDA approval for adjunctive treatment of MDD

MSD's Isentress for HIV-1 infection gets positive opinion from CHMP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...